Recent advances in the use of radiosensitizing nucleosides

Seminars in Radiation Oncology

Volumn 11, Issue 4, 2001, Pages 270-280

  McGinn, Cornelius J ^a,b   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; NUCLEOSIDE; RADIOSENSITIZING AGENT; TEGAFUR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER RADIOTHERAPY; DNA METABOLISM; DRUG DNA INTERACTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION;

EID: 0034788543     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.26002     Document Type: Article

References (70)

1. Fluoropyrimidine-radiation interactions in cells and tumors
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
3. Patient preferences for oral versus intravenous palliative chemotherapy
4. Fluorouracil: Biochemistry and pharmacology
5. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958)
6. Phase I-II studies of oral tegafur (ftorafur)
7. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats
8. Oral fluoropyrimidines in cancer treatment
9. Multicenter phase II study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
10. Randomized comparative study of orzel (oral uracil/tegafur (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
11. UFT/leucovorin vs 5-FU/leucovorin in colon cancer
12. The effects of leucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization
13. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer
14. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer
15. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer
16. Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin
17. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
18. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
19. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
20. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
21. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
22. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
23. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
24. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
25. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
26. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
27. A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
28. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
29. Capecitabine combined with simultaneous radiotherapy in rectal cancer: A phase I study
30. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
31. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
32. Nucleotide specificity of human deoxycytidine kinase
33. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine
34. 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
35. Action of 2′,-2′-difluorodeoxycytidine on DNA synthesis
36. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
37. Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′→5′ exonuclease-) fragment
38. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of sell-potentiation
39. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomized trial
40. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
41. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
42. Effect of 2,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro
43. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
44. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine)
45. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
46. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
47. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
48. The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
49. Radiosensitizing nucleosides
50. Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed field gel electrophoresis
51. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis
52. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine
53. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
54. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine)-mediated radiosensitization
55. Enhancement of tumor radioresponse in vivo by gemcitabine
56. Maximizing therapeutic gain with gemcitabine and fractionated radiation
57. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
58. Gemcitabine with thoracic radiotherapy - A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer
59. Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies
60. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer
61. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
62. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
63. Difluorodeoxycytidine (dFdC) - Gemcitabine: A phase I study
64. A phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer
65. A phase I study of preoperative gemcitabine with radiation therapy followed bt postoperative gemcitabine in patients with localized, resectable pancreatic adenocarcinoma
66. Treatment related toxicities with rapid-fractionation external beam radiation therapy and concomitant gemcitabine for locally advanced nonmetastatic adenocarcinoma of the pancreas
67. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas
68. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma
69. Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity
70. Final report of a phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in advanced pancreatic cancer